Apixaban: Third oral anticoagulant to compete with warfarin

Abstract

FDA finally approved apixaban (Eliquis—Bristol-Myers Squibb, Pfizer), an oral factor Xa inhibitor, in early January after a 6-month delay. In June 2012, the agency requested additional information from the manufacturer on "data management and verification" from ARISTOTLE, one of the landmark clinical trials supporting the drug's approval.